Clinical efficacy data is from FDA-approved branded GLP-1 medications (Mounjaro, Zepbound, Wegovy, Ozempic)
By combining appetite regulation with increased energy expenditure, retatrutide supports weight loss through two major mechanisms: Reduced caloric intake from improved satiety Increased metabolic activity that helps burn stored fat This dual action helps explain why retatrutide is often associated with more pronounced weight loss compared to therapies that rely on appetite suppression alone
Weve spent the last two years drawing on Nooms deep expertise in behavior change to create the ultimate GLP-1 companion program to solve the medications twin challenges, persistence and muscle-mass loss, while also driving enhanced weight loss outcomes
Cai X, She M, Xu M, Chen H, Li J, Chen X, Zheng D, Liu J, Chen S, Zhu J